Condition

Acute Agitation

ClinicalTrials.gov condition label

Clinical trials2

Recruiting0

Common interventions6

Lead sponsors shown2

Clinical trials

2 shown

A Study of Olanzapine in Patients With Acute AgitationNCT05803642 · 2023-03-28

UNKNOWN

Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101NCT03624322 · 2018-08-05

COMPLETED

Common interventions

HaloperidolDRUG1I231 POD® DeviceDEVICE1INP105DRUG1OlanzapineDRUG1ZydisDRUG1Zyprexa IMDRUG1

Leading sponsors

Impel Pharmaceuticals1Qilu Pharmaceutical Co., Ltd.1

Trial status mix

COMPLETED1

UNKNOWN1

Phase mix

PHASE11

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.